secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xencor Inc (XNCR)
CIK:        0001326732
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001326732-23-000039
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xencor receives $215M royalty payment, Q3 net loss $(0.40)/share; cash runway into 2027
--------------------------------------------------------------------------------

- Royalty transaction with OMERS yields $215M upfront for portions of Ultomiris and Monjuvi royalties; cash runway extended to 2027.
- Q3 revenue $59.2M, net loss $24.3M ($0.40 EPS) vs net loss $32.8M ($0.55 EPS) in Q3 2022.
- Discontinued XmAb104 (PD-1 x ICOS) after Phase 1 expansion missed efficacy criteria; narrowed vudalimab enrollment.
- Converted Genentech IL-15 co-development to milestone/royalty; plans to file IND for CLDN6 x CD3 (XmAb541) by year-end.
- CFO John Kuch to retire March 2024; search for replacement initiated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326732/000132673223000039/0001326732-23-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326732/000132673223000039/xncr-20231107.htm
  HTML page:      https://secwatch.observer/filing/0001326732-23-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer